Trovagene (NASDAQ: TROV) reported Q2 EPS of ($0.34), $0.03 worse than the analyst estimate of ($0.31).

"I'm excited to be part of the Trovagene team," said Bill Welch, Chief Executive Officer of Trovagene. "We announced a number of significant clinical study results, publications, and new collaborations with leading comprehensive cancer centers in the second quarter. Our focus remains on commercializing our highly sensitive and quantitative liquid biopsy tests, and we are pleased with our progress as our technology continues to show superior performance in both urine and blood in a variety of cancer types."

For earnings history and earnings-related data on Trovagene (TROV) click here.